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Objectives We hypothesized that cardiac myocyte-specific overexpression of caveolin-3 (Cav-3), a muscle-specific caveolin,
would alter natriuretic peptide signaling and attenuate cardiac hypertrophy.
Background Natriuretic peptides modulate cardiac hypertrophy and are potential therapeutic options for patients with heart
failure. Caveolae, microdomains in the plasma membrane that contain caveolin proteins and natriuretic peptide
receptors, have been implicated in cardiac hypertrophy and natriuretic peptide localization.
Methods We generated transgenic mice with cardiac myocyte-specific overexpression of caveolin-3 (Cav-3 OE) and also
used an adenoviral construct to increase Cav-3 in cardiac myocytes.
Results The Cav-3 OE mice subjected to transverse aortic constriction had increased survival, reduced cardiac hypertro-
phy, and maintenance of cardiac function compared with control mice. In left ventricle at baseline, messenger
ribonucleic acid for atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) were increased 7- and
3-fold, respectively, in Cav-3 OE mice compared with control subjects and were accompanied by increased pro-
tein expression for ANP and BNP. In addition, ventricles from Cav-3 OE mice had greater cyclic guanosine mono-
phosphate levels, less nuclear factor of activated T-cell nuclear translocation, and more nuclear Akt phosphoryla-
tion than ventricles from control subjects. Cardiac myocytes incubated with Cav-3 adenovirus showed increased
expression of Cav-3, ANP, and Akt phosphorylation. Incubation with methyl--cyclodextrin, which disrupts cave-
olae, or with wortmannin, a PI3K inhibitor, blocked the increase in ANP expression.
Conclusions These results imply that cardiac myocyte-specific Cav-3 OE is a novel strategy to enhance natriuretic peptide ex-
pression, attenuate hypertrophy, and possibly exploit the therapeutic benefits of natriuretic peptides in cardiac
hypertrophy and heart failure. (J Am Coll Cardiol 2011;57:2273–83) © 2011 by the American College of Cardi-
ology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2010.12.032In response to chronic stress, the heart undergoes hypertro-
phy that can progress to adverse remodeling and heart
failure. The signaling events in this progression are complex
and involve cell surface receptors, signal transduction path-
ways, and transcriptional and post-transcriptional events
(1). The subcellular organization of signaling components in
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functions, including cell growth
and hypertrophy (4). These mol-
ecules include: G-protein cou-
pled receptors, natriuretic pep-
tide receptors, heterotrimeric
G-protein subunits, G-protein-
regulated effectors, and PI3 ki-
nase (PI3K) (5,6).
There are 3 caveolin isoforms:
caveolin 1, 2, and 3 (7). Caveo-
lin-3 (Cav-3) is an isoform pre-
dominantly found in skeletal and
cardiac muscle. Caveolin-3
knockout mice develop periph-
eral muscle myopathic changes,
cardiac hypertrophy, and cardio-
myopathy (8). By contrast, over-
expression of caveolin-3 (Cav-3
OE) in neonatal cardiac myo-
cytes (CMs) results in the inabil-
ity of an adrenergic agonist (i.e.,
phenylephrine) and endothelin-1
to induce myocyte hypertrophy
(9). Thus, loss of Cav-3 induces
cardiac hypertrophy and cardio-
myopathy, and increased Cav-3
in CMs attenuates hypertrophy.
Natriuretic peptides have numerous actions that inhibit
hypertrophy; these include diuretic, natriuretic, and vasodi-
latory properties as well as autocrine/paracrine actions on
CMs (10–12). In atrial myocytes, atrial natriuretic peptide
(ANP) is secreted from caveolae and found closely associ-
ated with Cav-3 (5,13). Little is known about the role of
caveolae and caveolins in natriuretic peptide biology in
ventricular CMs. Although prior studies have implicated a
role for Cav-3 and caveolae in cardiac hypertrophy (9),
relationships among caveolin expression, natriuretic peptide
signaling, and cardiac hypertrophy have not been described.
In the current study, we show that CM-specific Cav-3 OE
attenuates cardiac hypertrophy and increases natriuretic
peptide expression and signaling.
Methods
Animals. Animals were treated in compliance with the
Guide for the Care and Use of Laboratory Animals (Na-
tional Academy of Science), and protocols were approved by
the Veterans Affairs San Diego Healthcare System Institu-
tional Animal Care and Use Committee. Animals were kept
on a 12-h light/dark cycle in a temperature-controlled room
with ad libitum access to food and water. A subset of Cav-3
OE mice and control littermates were individually housed
so that food and water intake could be measured daily.
Abbreviations
and Acronyms
ANP  atrial natriuretic
peptide
BNP  brain natriuretic
peptide
Cav  caveolin
Cav-3 OE  overexpression
of caveolin-3
cDNA  complementary
deoxyribonucleic acid
cGMP  cyclic guanosine
monophosphate
CM  cardiac myocyte
LV  left
ventricle/ventricular
MCD  methyl--
cyclodextrin
NFATc3  nuclear factor of
activated T-cell
PI3K 
phosphatidylinositol-3-kinase
RNA  ribonucleic acid
TAC  transverse aortic
constriction
WGA  wheat germ
agglutininTransgenic mice were generated in our laboratory with thealpha-myosin heavy chain promoter to produce CM-
specific Cav-3 OE (14). In some experiments, we isolated
CMs from 200- to 300-g male Sprague-Dawley rats.
Concentrations of sodium ion and potassium ion in
plasma and urine were determined in a subset of animals
with a flame photometer (Cole-Parmer Instrument Com-
pany, Vernon Hills, Illinois) as described previously (15).
A subset of Cav-3 OE and control mice were trained to
allow conscious blood pressure measurements without an-
esthesia with the CODA noninvasive tail blood pressure
system (Kent Scientific, Torrington, Connecticut). Data
were analyzed with the CODA version 2.5 software.
Transverse aortic constriction. Eight- to sixteen-week-
old transgenic Cav-3 OE mice and transgene negative
littermate mice (control) underwent transverse aortic con-
striction (TAC), as previously described (16). In brief, mice
were anesthetized with isoflurane, intubated, and mechan-
ically ventilated. An incision was made in the second
intercostal space, a 7-0 silk suture was placed around the
aorta, and a 27-g needle was placed between the innominate
and left carotid artery. A double surgeon’s knot was tied
down to the aorta and needle, and the needle was removed,
resulting in a 0.41-mm stenosis. Mice were allowed to
recover with 100% oxygen for 1 h. Mice were killed after 4
weeks of TAC. Sham animals underwent all aspects of the
surgery except placement of the stenosis.
Echocardiography. Echocardiography was performed in a
subset of Cav-3 OE and control mice before TAC surgery
and before killing. Mice were anesthetized with isoflurane,
and echocardiography was performed with a L15/6-MHz
transducer (Sonos 5500, Philips Medical Systems, Andover,
Massachusetts). Mice were evaluated for presence of trans-
verse aortic stenosis with pulse wave Doppler; all animals
had 3.5 m/s gradient across the stenosis. Bilateral carotid
catheterization performed in pentobarbital-anesthetized
mice by the use of 2 high-fidelity 1.4-F microtip pressure
transducers 48 h after TAC showed mean pressure gradients
between 40 and 50 mm Hg for both experimental groups
(p  NS, control vs. Cav-3 OE, n  5/group).
Cardiac function. A subset of Cav-3 OE and control mice
were anesthetized with pentobarbital, and cardiac catheter-
ization was performed with a high-fidelity 1.4-F microtip
pressure transducer (SPR-671, Millar Instruments, Inc.,
Houston, Texas). The catheter was advanced via the right
carotid artery into the left ventricle (LV) after measuring
systolic, diastolic, and mean arterial pressure. Parameters
were determined by an algorithm from EMKA Technolo-
gies (Falls Church, Virginia).
Morphological measurements. Dissected mouse hearts
were placed in ice-cold saline to evacuate remaining blood
before dissecting atria and ventricles. Dissected tissue was
dried on gauze, immediately weighed, and frozen. Heart
weight was defined as that of the left and right ventricles.
Lungs and tibias were also dissected. Lungs were dried on
gauze to remove excess blood and then weighed. Tibias were
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calipers.
Histology. Animals were transcardially perfused with ice-
cold cardioplegic solution (20 mmol/l potassium chloride)
and then with either 10% formalin or 4% paraformaldehyde
in phosphate buffer (pH  7.4) and removed. Tissues were
xed overnight at 4°C and embedded in paraffin. Fibrosis
as assessed with Masson’s Trichrome staining (Sigma, St.
ouis, Missouri) and hematoxylin-eosin staining of 5-m
sections.
For wheat germ agglutinin (WGA) immunofluores-
cence, 5-m sections of hearts were prepared, washed in
BS, incubated for 2 h in WGA-Alexa 488 lectin
Invitrogen, Carlsbad, California), and washed and
ounted in anti-fade reagent. Five images (40) from
ach heart were taken, and the diameter and areas from
0 to 100 of cross-sectionally arranged myocytes were
easured individually and analyzed with National Insti-
utes of Health ImageJ software.
lectron microscopy. Electron microscopy was performed
n a subset of Cav-3 OE and control whole hearts as
reviously described (14).
lasma peptide extraction and enzyme immunoassay.
lasma ANP and brain natriuretic peptide (BNP) concen-
rations were determined by fluorescent immunoassay kits
Phoenix Pharmaceuticals, Inc., Burlingame, California).
lasma was isolated from mouse blood obtained by cardiac
uncture from a subset of Cav-3 OE and control littermate
nimals. Peptides were extracted from the plasma with an
stablished protocol (Phoenix Pharmaceuticals) that in-
olved addition of an acidifying buffer and centrifugation
f samples at 17,000 g for 20 min at 4°C. The acidified
lasma was loaded on a pre-equilibrated C-18 SEP-
olumn (Phoenix Pharmaceuticals) and then eluted for
nalysis of eluted proteins by use of enzyme immunoassay
it protocols.
yclic guanosine monophosphate assay in mouse heart.
or cyclic guanosine monophosphate (cGMP) measure-
ents, hearts from control and Cav-3 OE mice were
eighed (n  5 to 6 hearts) and homogenized in 10
olumes of cold 5% trichloroacetic acid with a polytron
omogenizer. Samples were centrifuged at 1,500 g for 10
in, and the supernatants were then extracted with water-
aturated ether. The cGMP was measured in acetylated
upernatants with an enzyme immunoassay kit (Cayman
hemical, Ann Arbor, Michigan). The cGMP content is
xpressed as fmol/mg wet tissue.
solation of CMs. Cardiac myocytes were isolated from
dult male Sprague-Dawley rats (250 to 300 g) as previously
escribed (17). The CMs were incubated with 1.0  108
plaque-forming units Cav-3 adenovirus or green fluorescent
protein adenovirus (Control) for 24 h.
Immunoblotting. Whole tissue homogenates and cell
lysates (prepared as previously described [14]), nuclear
and cytoplasmic fractions (18), or blood samples were sseparated by sodium dodecylsulfate-polyacrylamide gel
electrophoresis with 10% polyacrylamide precast gels
(Invitrogen, Carlsbad, California) and transferred to
polyvinylidene difluoride membranes via electroelution.
Membranes were blocked in 20 mmol/l tris buffered
saline Tween (1%) containing 3% bovine serum albumin
and incubated with primary antibodies (Cav-3 and ANP,
Santa Cruz Biotechnology, Santa Cruz, California; PErk,
PAKT, and TAKT, Cell Signaling, Danvers, Massachu-
setts; glyceraldehyde-3-phosphate dehydrogenase, Im-
genex, San Diego, California) overnight at 4°C. Blots
were visualized with secondary antibodies conjugated
with horseradish peroxidase (Santa Cruz Biotechnology)
and enhanced chemiluminescence reagent (GE Health-
care, Waukesha, Wisconsin).
Quantitative real-time polymerase chain reaction analysis.
Total ribonucleic acid (RNA) was isolated from CM with a
RNeasy Mini Kit (Qiagen, Valencia, California). First
strand complementary deoxyribonucleic acid (cDNA) syn-
thesis (iScript cDNA synthesis kit, Bio-Rad, Hercules,
California) was performed with random hexamers on 1 to 2
g of total RNA. The concentration of cDNA was deter-
mined and adjusted to 50 ng/l for real-time polymerase
chain reaction analysis, which was performed on a MJ
Research Opticon 2 (Bio-Rad) in triplicate with the IQ
SYBR Green Supermix (Bio-Rad) with 100 ng cDNA and
0.5 mol/l forward/reverse primer mix in 20 l final
reaction volume. The ANP, BNP, and alpha-myosin heavy
chain primers were QuantiTect Primers (Qiagen) (primer
sequences for alpha-sk-actin forward: GTGTCACCCA-
CAACGTGC, reverse: AGGGCCACATAGCACAGC;
-myosin heavy chain forward: GCTGAAAGCAGAAA-
GAGATTATC, reverse: TGGAGTTCTTCTCTTCTG-
GAG). Thermal cycler conditions were as follows: 94°C-10
min (1 cycle); 94°C-20 s, 55°C-20 s, and 72°C-30 s (40 cycles).
Resulting polymerase chain reaction products were confirmed
by melt curve analysis. Analysis of cycle threshold was per-
formed with Opticon 2 analysis software (Bio-Rad); normal-
ized values were obtained for each group by subtracting
matched glyceraldehyde-3-phosphate dehydrogenase cycle
threshold values.
Statistics. Statistical analysis was performed with
GraphPad Prism Software (version 4.0, GraphPad, La
Jolla, California). All values are presented as mean 
SEM. One-way analysis of variance, followed by post-
hoc Bonferroni correction for multiple comparisons
(Figs. 1C, 2A to 2F, and 5C) (all comparisons were
performed, and all p values were corrected) and unpaired and
paired Student t test (Figs. 1D, 3C to 3F, 4A to 4F, and 5D) were
sed. A Kaplan-Meier analysis was performed on mouse survival
fter TAC banding (Fig. 1A), and significance was calculated
ith a log-rank test. A p value 0.05 was considered statisticallyignificant.
a
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o
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Cardiac myocyte-specific Cav-3 OE increases survival,
attenuates cardiac hypertrophy, and maintains cardiac
function in vivo. The Cav-3 OE and control mice
underwent 4 weeks of TAC to produce pressure-induced
cardiac hypertrophy. A log-rank test on a Kaplan-Meier
survival curve revealed that Cav-3 OE mice have in-
creased survival after TAC (Fig. 1A). Control mice
showed an increase in concentric hypertrophy, nearly
doubling heart size in response to TAC, but TAC
produced less hypertrophy in Cav-3 OE mice (Fig. 1B).
Transverse aortic constriction nearly doubled the ratio of
LV to body weight and tibia length in control mice, but
these changes were blunted in Cav-3 OE mice with TAC
(Fig. 1C). Cardiac hypertrophy, assessed by WGA stain-
ing of LV cross-sections, was reduced in Cav-3 OE mice.
Surface area of CMs from control TAC-treated mice was
nearly 60% greater than that of myocytes from Cav-3 OE
mice subjected to TAC (Fig. 1D). Echocardiography
confirmed that Cav-3 OE mice had a blunted hypertro-
Figure 1 Effects of Cav-3 OE on Mortality, Ventricular Size, and
(A) Kaplan-Meier curves show improved survival in overexpression of caveolin-3 (C
p  0.05; n  12 to 16. (B) Left ventricle (LV) cross sections reveal that Cav-3 O
hearts of control mice. (C) The LV to body weight (BW) and tibia length (TL) ratios
in Cav-3 OE mice. ***p  0.001, **p  0.01; n  8 to 16. (D) Adult cardiac
sectional area after TAC, as determined by wheat germ agglutinin staining (40
hearts of control mice but to a much lesser extent in hearts of Cav-3 OE mice.phic response to TAC compared with control subjects.Although, Cav-3 OE mice had a hypertrophic response
in interventricular septal wall thickness at end diastole
and LV posterior wall thickness at end diastole after
TAC banding, hypertrophy was attenuated compared
with control mice; no changes were observed in interven-
tricular septal wall thickness at end systole or LV poste-
rior wall thickness at end systole (Table 1). The Cav-3
OE mice also had less perivascular and interstitial cardiac
fibrosis associated with TAC (Fig. 1E).
Serial echocardiography revealed that control mice had
decreased ejection fraction and percentage fractional
shortening after 4 weeks of TAC (Figs. 2A and 2B),
whereas Cav-3 OE mice subjected to TAC had no
change in either measure of cardiac function. Carotid
catheterization showed that control mice but not Cav-3
OE mice had reduced LV systolic function (dP/dtmax)
fter 4 weeks of TAC (Fig. 2C). Thus, Cav-3 OE mice
aintained LV function in the presence of pressure
verload. Furthermore, LV relaxation (dP/dtmin) was
decreased in control mice but not Cav-3 OE mice after 4
diac Fibrosis After TAC
E) mice compared with control mice after transverse aortic constriction (TAC).
rts have significantly less concentric hypertrophy after TAC when compared with
creased significantly in control mice after TAC, whereas these ratios are blunted
ytes (CM) from Cav-3 OE mice have an approximately 60% decrease in cross-
*p  0.001; n  7. (E) TAC produces interstitial and perivascular fibrosis inCar
av-3 O
E hea
are in
myoc
). **weeks of TAC (Fig. 2D), a result consistent with the
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weight to body weight and tibia length ratios were
increased in control but not Cav-3 OE mice after TAC,
suggesting that control mice had increased fluid accumu-
lation consistent with heart failure (Fig. 2E).
Natriuretic peptide expression in Cav-3 OE mice at
baseline. The LVs from Cav-3 OE mice showed an
increased number of caveolae in the sarcolemmal membrane
(Fig. 3A), a result consistent with previous observations
(14). To define a role for natriuretic peptides as a mecha-
nism for the attenuation of cardiac hypertrophy in Cav-3
OE mice, we examined fetal gene expression. The RNA
isolated from LV homogenates showed a nearly 7- and
3-fold increase in ANP and BNP expression, respectively,
when compared with transgene negative littermates (con-
Figure 2 Physiological Assessment of Cardiac Function in Cav-
(A and B) Echocardiography in control and Cav-3 OE mice reveals a significant dec
Cav-3 OE mice after TAC. *p  0.05 versus control; n  8. (C and D) Carotid cat
in control mice but not Cav-3 OE mice 4 weeks after TAC. **p  0.01 versus con
(TL) ratios are significantly increased in control mice but not Cav-3 OE mice after Ttrol) with little to no difference in other fetal genes(Fig. 3B). Consistent with the change in RNA expression,
ANP and BNP protein expression in LV (Figs. 3C and 3D)
were also increased in Cav-3 OE mice. However, plasma
ANP and BNP levels were not significantly different be-
tween control and Cav-3 OE mice (Figs. 3E and 3F). We
also observed no significant differences in conscious blood
pressures (136 6 mm Hg for Cav-3 OE, and 141 3 mm
Hg for control subjects, p  NS, n  11/group), water or
food intake, natriuresis, or diuresis between control and
Cav-3 OE mice (Table 2).
Cav-3 OE mice have increased natriuretic peptide receptor A
expression and cGMP levels, reduced nuclear factor of
activated T-cells nuclear translocation and increased nuclear
pAkt. Left ventricular homogenates from Cav-3 OE and
control littermates were immunoblotted for natriuretic pep-
and Control Mice
in ejection fraction and percentage fractional shortening in control mice but not
ation reveals loss in LV systolic function (dP/dtmax) and LV relaxation (dP/dtmin)
p  0.05; n  8. (E) Wet lung weight (Lung) to body weight (BW) and tibia length
p  0.05 versus control; n  5 to 8. Abbreviations as in Figure 1.3 OE
rease
heteriz
trol, *
AC. *tide receptor A (NPR-A), the dominant receptor involved
g
a
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expression was increased in Cav-3 OE mice (Fig. 4A) and
that, consistent with the signaling by NPR-A, cGMP levels
were also increased in those mice (Fig. 4B). To investigate
downstream signaling molecules involved in hypertrophy,
we isolated nuclear and cytoplasmic fractions from Cav-3
OE and control LV homogenates and assessed the expres-
sion and localization of nuclear factor of activated T-cells
(NFATc3) and Akt. The LV from Cav-3 OE mice had a
reater cytoplasmic/nuclear ratio of NFATc3 (Figs. 4C
Figure 3 Caveolae Formation and Analysis of NP and Fetal Gen
(A) Electron microscopy of the LV reveals an increased number of plasma membra
ase chain reaction shows a nearly 7- and 3-fold increase in atrial natriuretic peptid
transgene negative (control) mice, whereas other “fetal genes” remain at levels si
increased in Cav-3 OE LV homogenates *p  0.05; n  4. (E and F) Mean circula
glyceraldehyde-3-phosphate dehydrogenase; MHC  myosin heavy chain; other abnd 4D) and decreased cytoplasmic/nuclear expression ofpAkt due to increased nuclear expression than did LV
from control littermates (Figs. 4E and 4F).
ANP expression is caveolae-dependent and dependent
on Akt phosphorylation. To assess whether increased
expression of caveolins or caveolae were alone sufficient to
observe the increase in ANP expression, we isolated ven-
tricular CM from adult Sprague-Dawley rats and treated
them with increasing Cav-3 adenovirus (from 0 to 30 107
plaque-forming units) for 24 h (Fig. 5A). We found that
Cav-3 expression, ANP expression, and Akt phosphoryla-
pression in Cav-3 OE and Control Mice
veolae in Cav-3 OE mice. Scale bar  0.10 mm; n  2. (B). Real-time polymer-
P) and brain natriuretic peptide (BNP), respectively (Cav-3 OE), compared with
o control mice. n  5 to 6. (C and D) ANP and BNP expression are significantly
lasma ANP and BNP levels are similar in Cav-3 OE and control mice. GAPDH 
ions as in Figure 1.e Ex
ne ca
e (AN
milar t
ting p
breviattion all increased in CM incubated with the Cav-3 adeno-
2279JACC Vol. 57, No. 22, 2011 Horikawa et al.
May 31, 2011:2273–83 Caveolin and Natriuretic Peptidesvirus but that adenovirus for enhanced green fluorescent
protein (control) produced no increase in Cav-3, ANP, or
pAkt expression (Fig. 5A).
To determine whether Cav-3 expression or the formation
of caveolae was involved in the increase in ANP expression,
we incubated CM for 24 h with methyl--cyclodextrin
(MCD) (500 nmol/l), an agent that disrupts caveolae,
during incubation with the Cav-3 adenovirus. MCD
disrupted caveolae (Fig. 5B), and in the presence of MCD,
neither ANP nor pAkt expression increased even though
Cav-3 was substantially increased (Fig. 5C). Thus, the
presence of caveolae seems to be necessary for the increase in
ANP expression in CM engineered to overexpress Cav-3.
To assess the role of Akt in ANP expression, we
incubated CM with Cav-3 adenovirus for 24 h in the
presence of wortmannin, a PI3K inhibitor, or dimethyl
sulfoxide (vehicle). Wortmannin decreased Akt phosphor-
ylation and ANP expression in myocytes incubated with
Figure 4 Elevated NPR-A Expression Increases cGMP Leading
(A) Natriuretic peptide receptor A (NPR-A) expression is significantly increased in C
monophosphate (cGMP) is significantly increased in Cav-3 OE mice compared with
from control and Cav-3 OE LV probed for NFATc3 show that Cav-3 OE mice have a
*p  0.05; n  5. (E and F) Nuclear and cytoplasmic fractions from control and C
pAkt in the cytoplasm compared with control mice. *p  0.05; n  5. AbbreviatioCav-3 adenovirus (Fig. 5D), thus implying that the in-creased ANP expression in response to Cav-3 OE is
dependent on Akt phosphorylation.
Discussion
Our results show that CM-specific Cav-3 OE blunts
pressure-induced cardiac hypertrophy and increases natri-
uretic peptide expression and downstream signaling. This
increase in natriuretic peptide expression depended on the
presence of caveolae and was associated with increased
phosphorylation of Akt. Thus, increasing cardiac Cav-3
expression might provide a novel therapeutic approach to
enhance natriuretic peptide expression.
The localization of natriuretic peptides with caveolae
and caveolins was suggested 20 years ago, but little
further work has investigated these relationships
(5,13,19). Previously we have shown that CM-specific
Cav-3 OE mimics ischemia-induced preconditioning and
protects the heart from ischemic injury by increasing pAkt
reased Nuclear Phophorylated AKT
E mice compared with control mice. *p  0.05; n  3. (B) Cyclic guanosine
l mice. *p  0.05; n  5 to 6. (C and D) Nuclear and cytoplasmic fractions
cantly higher ratio of NFATc3 in the cytoplasm compared with control mice.
E LV probed for pAkt show that Cav-3 OE mice have a significantly lower ratio of
in Figures 1 and 3.to Inc
av-3 O
contro
signifi
av-3 O
ns assignaling, effects that are blocked with 5-hydroxydecanoate, a
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Caveolin and Natriuretic Peptides May 31, 2011:2273–83Figure 5 CM Treated With Cav-3 Adenovirus Have Increased ANP Expression and Akt Phosphorylation
That Is Decreased by Disruption of Caveolae With MCD and the PI3K Inhibitor, Wortmannin
(A) CM isolated from Sprague-Dawley rats were infected with increasing plaque-forming units (pfu) of adenovirus expressing Cav-3. ANP expression and Akt phosphoryla-
tion increased in parallel with the increase in Cav-3 expression. (B and C) CM treated with methyl--cyclodextrin (MCD) for 24 h during the period of incubation with
1.0  107 pfu Cav-3 adenoviral particles have a decrease in number of caveolae, even though Cav-3 expression increased in MCD-treated CM, whereas ANP expres-
sion and Akt phosphorylation decreased. Scale bar  0.10 mm. *p  0.05; n  4 (D) Incubation with wortmannin for 24 h inhibited Akt phosphorylation and ANP
expression of CM incubated with 1.0  107 pfu Cav-3 adenovirus. *p  0.05; n  3. Abbreviations as in Figures 1 and 3.
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I3K inhibitor (14). Treatment of rat hearts with ANP also
as cardioprotective effects that are blocked with
-hydroxydecanoate (20). The Cav-3 knockout mice display
nhanced hypertrophic signaling (8), an effect similar to that
bserved in mice with a knockout of NPR-A, the major
atriuretic signaling receptor in CMs (21). The current results
how that Cav-3 OE mice are resistant to pressure-induced
ypertrophy, potentially as a consequence of increased natri-
retic peptide and NPR-A expression accompanied by in-
reased cGMP and pAkt signaling. Our conclusion is consis-
ent with previous work that has documented the
ntihypertrophic (22), antifibrotic (23), and inotropic (24)
ctions of natriuretic peptides.
Overexpression of NPR-A has been shown to reduce
AC-induced cardiac hypertrophy via a nonmitogen-
ctivated protein kinase signaling pathway (25). The
PR-A has an intracellular guanylyl cylase domain, which
pon activation increases cGMP levels and can inhibit
ypertrophic signaling. The Cav-3 OE mice have increased
evels not only of NP but also of NPR-A and cGMP,
uggesting that NPR-A activity is increased. Although we
ave shown that phosphorylated endothelial nitric oxide
ynthase and nitric oxide synthase activity are not signifi-
antly elevated in cardiac homogenates of Cav-3 OE mice
14), recent studies suggest an interplay between ANP and
itric oxide (26) and implicate a synergistic augmentation of
Echocardiography MeasurementsTable 1 Echocardiography Measurements
Control
Sham
(n  8)
TAC
(n  8)
% Change (Pre- vs. P
(n  8)
IVSd (mm) 0.91 0.05 1.34 0.05* 47.9 12.2%
LVIDd (mm) 4.07 0.09 4.21 0.06 9.4 6.6%
LVPWd (mm) 0.79 0.05 1.25 0.07* 40.6 19.3%
IVSs (mm) 1.27 0.10 1.69 0.08¶ 27.8 15.1%
LVIDs (mm) 2.91 0.12 3.27 0.12 27.5 12.1%
LVPWs (mm) 1.11 0.11 1.53 0.07¶ 28.3 11.1%
Data represent absolute echocardiographic values for Sham and transverse aortic constriction (TAC
(%) change in echocardiographic values between the pre- (before TAC) and post-TAC (4 weeks aft
versus control TAC. ‡p  0.05 versus sham Cav-3 OE. §p  0.05 versus control percentage chan
IVSd interventricular septal wall thickness at end diastole; IVSs interventricular septal wall th
nternal dimension at end systole; LVPWd  left ventricular posterior wall thickness at end diasto
Food and Water Intake byC ntrol and Cav-3 OE MiceTable 2 Food and Water Intake byControl and Cav-3 OE Mice
Control
(n  8)
Cav-3 OE
(n  8)
Food intake (mg/day) 4.13 0.11 3.75 0.12
Water intake (ml/day) 5.41 0.35 5.04 0.40
Plasma sodium (mmol/l) 150.5 1.00 151.5 0.87
Plasma potassium (mmol/l) 5.029 0.32 5.522 0.31
Urine-Na/creatinine (mmol/mmol) 32.21 5.84 36.42 6.35
Urine-K/creatinine (mmol/mmol) 30.19 8.04 36.65 4.13i
Sodium (Na) and potassium (K) level in plasma and urine of control and overexpression of
caveolin-3 (Cav-3 OE) mice.PR-A signaling via nitric oxide-activated guanylyl cyclases
27). The mechanism for this crosstalk will require further
nvestigation.
Akt localization in the nucleus can prevent cardiac hyper-
rophy, and nuclear Akt can induce ANP expression, prevent
athological hypertrophy, and maintain cardiac function after
AC (28). The increase in natriuretic peptides that occurs
ith cardiac hypertrophy might help compensate for the
ncrease in afterload via its diuretic, natriuretic, and vasodilat-
ng actions as well as by its ability to inhibit aldosterone
ynthesis and renin secretion (10–12). Natriuretic peptides
ave been used to reduce post-myocardial infarction remodel-
ng (29) and to improve stroke volume index in patients with
eart failure (24). However, the use of natriuretic peptides as
eart failure therapeutics has been hampered by the relatively
hort half-life and instability of ANPs and hypotension-
ependent reductions in renal perfusion that occur with BNP
30). The current data show that Cav-3 OE creates a cellular
ool of natriuretic peptides that can lead to long-term positive
ardiovascular effects in a setting of cardiac hypertrophy.
We find that increased Cav-3 expression in CMs is
ssociated with increases in pAkt and ANP expression
nd that the latter increases depend on caveolae expres-
ion and localization of Cav-3 in caveolae, because
CD treatment decreases caveolae but not Cav-3
xpression and significantly lowers pAkt and ANP ex-
ression (Fig. 5C). On the basis of results obtained with
ortmannin, which inhibits expression of pAkt and
NP, pAkt potentially contributes to the enhanced
xpression of ANP (28). Thus, our results imply that
aveolae not only localize ANP but might also decrease
ts degradation and facilitate the ability of PI3K and pAkt
o up-regulate ANP protein expression. We speculate that
he increase in natriuretic peptides in Cav-3 OE mice might
revent the dephosphorylation and thus decrease nuclear
ranslocation of NFATc3, thereby inhibiting cardiac hyper-
rophy (31). The Cav-3 OE mice also have greater nuclear
Akt expression, which perhaps contributes to their increase
Cav-3 OE
C) Sham
(n  8)
TAC
(n  11)
% Change (Pre- vs. Post-TAC)
(n  8)
0.88 0.05 1.10 0.05†‡ 18.0 6.2%§
3.85 0.08 4.09 0.17 7.9 4.4%
0.80 0.04 1.13 0.07 21.5 7.1%
1.20 0.08 1.46 0.07 6.6 6.6%
2.67 0.14 3.07 0.24 22.4 9.8%
1.17 0.07 1.41 0.09 12.4 7.8%
ls at 4 weeks in the control and overexpression of caveolin-3 (Cav-3 OE) groups and the percentage
measurements in the control and Cav-3 OE groups. *p  0.001 versus sham control. †p  0.01
0.01 versus sham Cav-3 OE. ¶p  0.05 versus sham control.
at end systole; LVIDd left ventricular internal dimension at end diastole; LVIDs left ventricular
Ws  left ventricular posterior wall thickness at end systole.ost-TA
) anima
er TAC)
ge. p n natriuretic peptide expression.
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Caveolin and Natriuretic Peptides May 31, 2011:2273–83Increased natriuretic peptide levels are generally thought
to reflect cardiac dysfunction and have been used as a
“biomarker” of cardiac hypertrophy (32). However, unlike in
other hypertrophic models, Cav-3 OE mice have increased
ANP and BNP RNA levels but not those of other hyper-
trophic markers. Thus, Cav-3 OE seems to have the unique
ability to alter natriuretic peptide levels without inducing
the complete fetal gene response, a result akin to the ability
of nuclear localization of pAkt to prevent hypertrophy (28).
Treatment with hypertrophic agonists can increase Cav-3
protein and caveolae formation, but it is not clear whether
this effect is harmful or helpful in the setting of cardiac
hypertrophy (9,33). The current results show that overex-
pressing caveolae and Cav-3 does not exacerbate but instead
prevents cardiac hypertrophy, thus implicating a protective
role for increased Cav-3 expression.
The current findings in mice with myocyte-specific Cav-3
OE contrast with data for mice with non–CM-specific Cav-3
OE, which develop a cardiomyopathy-like phenotype (34).
Cav-3 expression is normally limited to skeletal and cardiac
muscle, and as a result, other effects of Cav-3 OE—such as
induction of vasculopathies—cannot be ruled out as the cause
of cardiac dysfunction in such mice.
Study limitations. A limitation of the current study was
hat we did not directly investigate the role of NPR-A
ntagonism on downstream hypertrophic signaling. We
ere unable to obtain an inhibitor of NPR-A (e.g., HS-
42-1, which was used in some prior studies but is no longer
anufactured).
onclusions
he data shown here indicate that a plasma membrane
tructural protein, Cav-3, not only increases caveolae for-
ation but also induces a “protective phenotype” that is
haracterized by increased natriuretic peptide expression
nd decreased cardiac hypertrophy. The present data thus
efine a physiologically important relationship between
av-3 and natriuretic peptide levels in the LV and identify
novel mechanism and therapeutic rationale for the poten-
ial of increasing Cav-3 expression to enhance the expres-
ion of natriuretic peptides and their beneficial effects
gainst heart failure.
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